Allianz Asset Management GmbH Trims Stake in Hologic, Inc. (NASDAQ:HOLX)

Allianz Asset Management GmbH lessened its position in Hologic, Inc. (NASDAQ:HOLX) by 20.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 367,785 shares of the medical equipment provider’s stock after selling 91,978 shares during the quarter. Allianz Asset Management GmbH’s holdings in Hologic were worth $26,514,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in the company. FMR LLC raised its holdings in Hologic by 64.0% in the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after purchasing an additional 2,174,093 shares in the last quarter. Nordea Investment Management AB increased its stake in shares of Hologic by 32.7% in the 4th quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock worth $159,911,000 after acquiring an additional 544,889 shares in the last quarter. Swedbank AB increased its stake in shares of Hologic by 18.8% in the 3rd quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock worth $157,788,000 after acquiring an additional 306,562 shares in the last quarter. JPMorgan Chase & Co. lifted its position in Hologic by 21.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider’s stock valued at $110,700,000 after acquiring an additional 238,222 shares during the period. Finally, Barclays PLC boosted its stake in Hologic by 47.6% during the third quarter. Barclays PLC now owns 718,231 shares of the medical equipment provider’s stock worth $58,507,000 after acquiring an additional 231,578 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Hologic

In other news, COO Essex D. Mitchell sold 24,856 shares of the company’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares of the company’s stock, valued at $2,134,237.38. This represents a 47.06 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.88% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

HOLX has been the subject of several recent research reports. Mizuho lowered their target price on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a report on Tuesday, November 5th. JPMorgan Chase & Co. raised their price objective on Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Wolfe Research began coverage on Hologic in a report on Friday, December 13th. They issued a “peer perform” rating on the stock. Leerink Partnrs downgraded Hologic from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th. Finally, StockNews.com upgraded shares of Hologic from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. Ten equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $85.77.

Hologic Stock Up 0.8 %

Shares of Hologic stock opened at $65.01 on Tuesday. Hologic, Inc. has a twelve month low of $62.69 and a twelve month high of $84.67. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The company’s 50 day moving average is $69.76 and its 200 day moving average is $76.41. The company has a market cap of $14.59 billion, a price-to-earnings ratio of 20.51, a price-to-earnings-growth ratio of 2.14 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.